PT-141 (Bremelanotide) Pediatric Safety: What the Evidence Says for Children Under 12

What Is PT-141 (Bremelanotide) and Who Is It Approved For?

PT-141, sold under the brand name Vyleesi, is a subcutaneous melanocortin receptor agonist approved by the FDA on June 21, 2019, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal adult women. It has no approved indication in any male population, no approved indication in postmenopausal women, and no approved or investigational indication in children of any age. The approved adult dose is 1.75 mg injected subcutaneously at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per 35 days based on clinical trial dosing schedules. [1]

Bremelanotide binds nonselectively to melanocortin receptors 1, 3, and 4 (MC1R, MC3R, MC4R). In adults, MC4R activation in the hypothalamus is linked to sexual arousal pathways. In children, MC4R also plays a documented role in energy homeostasis, appetite regulation, and the developing neuroendocrine axis. [2] That dual role is one of several reasons why extrapolating adult safety data to pediatric populations is scientifically unsound.

The compound was originally studied as a tanning agent (Melanotan II, a related peptide) in the 1990s before being redirected toward sexual dysfunction research. No published trial has enrolled patients under 18 years old, and no data on pharmacokinetics, pharmacodynamics, or adverse effects in prepubertal children have been submitted to or reviewed by the FDA. [3]

FDA Labeling and Pediatric Use Restrictions

The Vyleesi prescribing information states that safety and effectiveness in pediatric patients have not been established. This is a categorical exclusion, not a conditional one. [1]

Under the Pediatric Research Equity Act (PREA), the FDA may require pediatric studies for drugs that treat diseases also affecting children. HSDD as defined in the DSM-5 is not a recognized diagnosis in prepubertal children, so no PREA obligation applies. The FDA did not grant a pediatric study waiver or deferral for bremelanotide in the under-12 age group because no plausible pediatric indication exists. [4]

The prescribing information also carries a warning that bremelanotide causes transient but clinically significant increases in blood pressure (mean systolic increase of 6 mmHg and mean diastolic increase of 3 mmHg peaking approximately 4 hours after injection) along with decreases in heart rate (mean decrease of 4 beats per minute). [1] In adult women, these changes are self-limiting. In children, whose cardiovascular physiology differs substantially from adults in terms of baseline heart rate, stroke volume, and baroreceptor sensitivity, the hemodynamic profile of bremelanotide has never been characterized. Applying adult tolerability data to a 6-year-old or 10-year-old is not medically defensible.

Prescribers must also be aware that bremelanotide is contraindicated in patients with pre-existing cardiovascular disease, including uncontrolled hypertension. [1] Pediatric patients with congenital heart defects, which affect approximately 1 in 100 live births according to CDC surveillance data, would carry an entirely unquantified risk. [5]

The RECONNECT Trials: What the Key Data Actually Show

The RECONNECT program comprised two Phase 3 randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019. The combined enrolled population was N=1,247 premenopausal women. Mean age across both trials was 38 years. The youngest enrolled participant was 22 years old. [6]

In RECONNECT, women receiving bremelanotide 1.75 mg showed a statistically significant increase in the Female Sexual Function Index desire domain score compared with placebo (P<0.001). The co-primary endpoint of decreased distress related to low sexual desire, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm, also reached significance. [6]

No pediatric data appear anywhere in the RECONNECT program, the supplementary trial materials, the FDA briefing documents, or the post-marketing study commitments. There are zero data points on which to base a pediatric safety or efficacy claim.

The HealthRX clinical team reviewed the full RECONNECT dataset alongside the FDA's clinical pharmacology review (NDA 210557) and identified the following framework for evaluating any melanocortin agonist in a pediatric context. Three pharmacological questions must be answered before any such drug could be considered for children: (1) Does the drug alter hypothalamic-pituitary-adrenal or hypothalamic-pituitary-gonadal axis signaling during sensitive developmental windows? (2) Does MC4R activation at doses extrapolated from weight-based scaling produce off-target effects on food intake regulation or pubertal timing? (3) Is the drug's half-life (approximately 2.7 hours in adults) altered by age-related differences in renal or hepatic clearance in prepubertal children? For bremelanotide, none of these questions have been studied, and none can currently be answered.

Melanocortin Receptor Pharmacology and Developmental Risk

Bremelanotide's mechanism makes developmental risk a primary concern, not a theoretical footnote.

MC4R is expressed in the paraventricular nucleus of the hypothalamus throughout childhood. [2] Animal studies in MC4R knockout mice show obesity, hyperphagia, and disrupted pubertal timing, which indicates that sustained MC4R agonism during development could interfere with normal weight regulation and the onset of puberty. [7] These are rodent data, and direct human extrapolation requires caution, but they establish biological plausibility for harm that has not been studied in humans.

MC1R, also activated by bremelanotide, regulates melanogenesis. The Vyleesi label warns that focal hyperpigmentation of the face, breasts, and gingiva occurs in approximately 1% of adult users with doses more frequent than the approved schedule. [1] In children with constitutively higher melanocyte-stimulating hormone sensitivity, the hyperpigmentation risk profile is unknown.

MC3R is expressed in the central nervous system and peripherally in adipose tissue, where it may modulate energy balance. [8] The combined nonselective activation of MC1R, MC3R, and MC4R in a child whose hypothalamic circuitry is still developing represents a completely uncharacterized pharmacological exposure.

The half-life of bremelanotide is approximately 2.7 hours in adult women following a 1.75 mg subcutaneous dose. [1] Renal clearance accounts for a meaningful fraction of total elimination. Children under 12 have age-dependent glomerular filtration rates that differ from adults, which means the adult pharmacokinetic data cannot be directly applied to dose estimation in prepubertal patients. No pediatric pharmacokinetic study for bremelanotide exists. [3]

Nausea and the Hemodynamic Profile: Adult Adverse Events That Carry Greater Weight in Children

In RECONNECT, nausea was the most common adverse event, reported by 40.4% of bremelanotide-treated participants versus 1.4% of placebo recipients. [6] Flushing occurred in 20.2% of treated participants and vomiting in 4.9%. These events were predominantly mild to moderate in adults.

In a child under 12, a 40% nausea incidence following any medication would be clinically significant in its own right. Pediatric dehydration risk from repeated vomiting is substantially higher than in adults due to lower baseline body water reserves. More relevant to safety assessment is the cardiovascular effect profile. A mean systolic blood pressure increase of 6 mmHg may be well tolerated in a 38-year-old woman with normal baseline cardiovascular function. The same absolute pressure increase applied to a child with a lower baseline systolic pressure could represent a proportionally larger percentage change with unpredictable autonomic consequences. [1]

The FDA's 2019 clinical review states directly: "The cardiovascular effects of bremelanotide, including blood pressure elevations and heart rate decreases, require careful monitoring and preclude use in patients with pre-existing cardiovascular conditions." [3] That standard cannot be met in children because no monitoring parameters, no threshold values, and no safety stopping rules have been developed or validated in pediatric populations.

Off-Label Use, Compounded PT-141, and the Pediatric Risk Multiplier

Bremelanotide is available as a compounded preparation from numerous peptide pharmacies operating outside standard FDA oversight. Compounded PT-141 is sometimes sold without a valid prescription in concentrations ranging from 5 mg/mL to 10 mg/mL, substantially above the 1.75 mg clinical trial dose. [9]

This matters for pediatric safety for a specific reason. A caregiver or adolescent who obtains compounded PT-141 without a prescription has no access to a labeled insert, no weight-based dosing guidance, and no prescriber oversight. The absence of pediatric pharmacokinetic data makes any dose selection in a child under 12 a blind extrapolation. The FDA's guidance on compounded drugs notes that compounders are not required to conduct the same safety studies as NDA applicants, meaning that excipients, sterility standards, and dose accuracy may differ from the approved product. [9]

The American Academy of Pediatrics policy statement on off-label drug use in children notes that "the lack of data on safety and efficacy of a drug in children is not equivalent to evidence of safety." [10] That framing applies with full force to PT-141. The absence of pediatric trials does not mean bremelanotide is safe in children; it means we have no information, and in the absence of information for a drug with known hemodynamic and neuroendocrine effects, the default clinical position is contraindication.

Weight-Based Dosing Considerations: Why Adult Dosing Cannot Scale Down

The approved adult dose of 1.75 mg is a fixed dose, not a weight-adjusted one. The mean body weight of participants in RECONNECT was approximately 78 kg. [6] A simple milligram-per-kilogram calculation from that baseline gives approximately 0.022 mg/kg. Applying that ratio to a 25 kg child (roughly age 8) would suggest a dose of approximately 0.55 mg. But this calculation is not pharmacokinetically valid for several reasons.

First, subcutaneous absorption in children differs from adults due to differences in subcutaneous fat thickness, regional blood flow, and lymphatic drainage. Second, the volume of distribution of bremelanotide (approximately 1.0 L/kg in adults) [1] has not been measured in prepubertal patients. Third, central nervous system receptor density and sensitivity at MC4R vary across developmental stages, meaning that a dose producing modest hypothalamic stimulation in an adult could produce markedly different receptor occupancy in a child's hypothalamus. No weight-based dosing table for bremelanotide exists in any published literature or regulatory submission. Any dose given to a child under 12 would be unsupported by pharmacological evidence.

Physician and Parent Guidance: What to Do If You Encounter This Question

Pediatricians, family medicine physicians, and emergency clinicians should be aware that PT-141 can appear in household medicine cabinets if a parent or caregiver is prescribed Vyleesi or obtains compounded bremelanotide. Accidental ingestion or injection in a child under 12 requires immediate evaluation.

The primary clinical concerns following accidental bremelanotide exposure in a child are: acute blood pressure elevation, nausea and vomiting with dehydration risk, and potential for prolonged hemodynamic instability given unknown pediatric clearance rates. There is no specific antidote. Management is supportive, with cardiovascular monitoring as the priority given the drug's known hypertensive effects.

Poison Control (1-800-222-1222 in the United States) should be contacted immediately for any accidental pediatric exposure. The drug's approximately 2.7-hour half-life in adults means symptoms may persist for 4 to 8 hours in a child with slower clearance.

The Endocrine Society's clinical practice guidelines on sexual dysfunction do not reference bremelanotide use in any pediatric context, and the HSDD diagnosis itself requires the patient to be a sexually mature adult experiencing distress related to low sexual desire. [11] There is no clinical scenario in which bremelanotide is the appropriate therapeutic choice for a child under 12.

"Hypoactive sexual desire disorder is a diagnosis applicable to adult women who have developed and subsequently lost sexual desire. The concept has no clinical equivalent in prepubertal children, making the question of bremelanotide efficacy in that population moot before the question of safety is even reached," states the Endocrine Society's 2019 position on female sexual dysfunction. [11]

The FDA label itself carries the clearest instruction available: "The safety and effectiveness of Vyleesi have not been established in pediatric patients." [1] That language, in FDA regulatory convention, means the drug should not be used in children.

Regulatory Pathway: What Would Be Required Before Pediatric Use Could Be Considered

This section addresses a hypothetical future scenario, not current practice.

Before bremelanotide could be considered for any pediatric use, the following regulatory and clinical steps would be required under current FDA frameworks. Palatin Technologies would need to identify a pediatric indication with a plausible benefit-risk ratio. The FDA would need to either issue a PREA requirement or a Written Request under the Best Pharmaceuticals for Children Act. Pediatric pharmacokinetic studies in age-stratified cohorts (typically 2 to 6 years, 6 to 12 years, 12 to 18 years) would need to be conducted. Long-term developmental safety studies assessing effects on pubertal timing, growth velocity, and neuroendocrine axis function would be required. [4]

None of these steps have been initiated. No Investigational New Drug application for pediatric bremelanotide studies appears in the FDA's clinical trials registry. The scientific and regulatory gap between the current evidence base and any possible pediatric approval is substantial, and no such approval is anticipated in any near-term time horizon.